Myeloid Cells Targeting Therapeutics Market, 2021-2035

April 28, 2022

To order this 150+ page report, which features 100+ figures and 5+ tables, please visit

https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html

Key Inclusions

A detailed assessment the current market landscape of myeloid cells targeting therapeutics, based on several relevant parameters, such as phase of development (clinical and preclinical), type of molecule (small molecules and biologics), target indication, therapeutic area (oncological disorders, hepatic disorders, autoimmune disorders, inflammatory diseases, respiratory disorders, neurological disorders, renal disorders, rheumatological disorders, immunological disorders and others), biological target, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, it provides details on the companies engaged in the development of myeloid cells targeting therapeutics, along with information on their year of establishment, company size and location of headquarters.
Elaborate profiles of key players engaged in the development of myeloid cells targeting therapeutics. Each profile features a brief overview of the company, details on its drug candidates, its financial information (if available), recent developments and an informed future outlook.
A detailed analysis of completed and ongoing clinical trials of various myeloid cells targeting therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age category of the patients enrolled, active industry and non-industry players and location of the trials.
A detailed review of more than 10,000 peer-reviewed, scientific articles related to research on myeloid cells targeting therapeutics, based on parameters, such as year of publication, emerging focus area, type of publication, therapeutic area, and target indication. The chapter also highlights the top journals and top authors (in terms of number of articles published).
An in-depth analysis of academic grants that have been awarded to various research institutes for projects related to myeloid cell targeting therapeutics, during the period, 2017-2021, based on several parameters, such as year of grant award, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded) and prominent program officers.
An analysis of the partnerships that have been established in this domain since 2017, covering instances of research and development agreement, clinical trials agreement, merger / acquisition, product development and commercialization agreement, licensing agreement, asset acquisition and product development and manufacturing agreement.
A detailed analysis of the various investments made since 2017, including grants, seed financing, venture capital financing, IPOs, secondary offering, other equity, post IPO equity and equity crowdfunding in the companies focused on the development of myeloid cells targeting therapeutics.
An analysis of start-ups / small companies engaged in the development of myeloid cells targeting therapeutics, based on parameters, such as pipeline strength, pipeline maturity, indication diversity, financial support, number of investors, partnership activity and start-up health indexing.
A case study on the companies developing macrophage-based therapeutics, along with analyses on phase of development, type of molecule, target indication and therapeutic area. In addition, the chapter provides information on the year of establishment, company size and location of headquarters of the companies engaged in the development of these therapeutics.
A detailed market forecast, featuring analysis of the current and projected opportunity across key market segments (listed below)
- Type of Molecule
  - Small Molecule
  - Biologics
- Therapeutic Area
  - Oncological Disorders
  - Rare Disorders
- Type of Therapy
  - Combination Therapy
  - Monotherapy
- Route of Administration
  - Intravenous
  - Oral
- Geography
  - North America
  - Europe
  - Asia Pacific

To request sample pages, please visit

https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html

Key Questions Answered

Who are the leading players engaged in the development of myeloid cells targeting therapeutics?
Which are the key drugs being developed across early and late stages of development?
Which companies are actively involved in conducting clinical trials for myeloid cell targeting therapeutics?
What is the focus of various publications related to therapeutics targeting myeloid cells?
What kind of partnership models are commonly adopted by industry stakeholders engaged in the myeloid cells targeting therapeutics domain?
How is the current and future opportunity likely to be distributed across key market segments?

You may also be interested in the following titles: